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Summary 
Background​. Real-world data show that approximately 50% of psoriasis patients treated with a 
biologic agent will discontinue the drug because of loss of efficacy. History of previous therapy 
with another biologic, female sex and obesity were identified as predictors of drug 
discontinuations, but their individual predictive value is low.  
Objectives​. To determine whether machine learning algorithms can produce models that can 
accurately predict outcomes of biologic therapy in psoriasis on individual patient level.  
Results.​ All tested machine learning algorithms could accurately predict the risk of drug 
discontinuation and its cause (e.g. lack of efficacy vs adverse event). The learned generalized 
linear model achieved diagnostic accuracy of 82%, requiring under  2 seconds per patient using 
the psoriasis patients dataset. Input optimization analysis established a profile of a patient who 
has best chances of long-term treatment success: biologic-naive patient under 49 years, 
early-onset plaque psoriasis without psoriatic arthritis, weight < 100 kg, and moderate-to-severe 
psoriasis activity (DLQI ≥ 16; PASI ≥ 10).  Moreover, a different generalized linear model is used 
to predict the length of treatment for each patient with mean absolute error (MAE) of 4.5 
months. However Pearson Correlation Coefficient indicates 0.935 linear dependencies between 
the actual treatment lengths and predicted ones. 
Conclusions​. Machine learning algorithms predict the risk of drug discontinuation and treatment 
duration with accuracy exceeding 80%, based on a small set of predictive variables. This 
approach can be used as a decision making tool, communicating expected outcomes to the 
patient, and development of evidence-based guidelines.  
 
Introduction 
The unprecedented success and wide implementation of biologics in the therapy of psoriasis 
has over the last decade changed the landscape of the medical need in this disease. In the 
pre-biologic era, skin clearance was difficult to achieve and required a combination of multiple 
skin-directed therapies and systemic agents, with a significant risk of cumulative toxicities. 
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 Today, biologics allow us to achieve PASI 75 responses in up to 90% of the patients, and 
real-world evidence from registries confirms that a comparable proportion of psoriasis patients 
achieve excellent control of skin disease.​1,2​ Despite the vast amount of data on the efficacy of 
biologics, therapeutic decision-making (ie, deciding which treatment to administer for each 
individual patient) is still based on a trial-and-error approach. The initial choice of therapy is not 
always optimal, as reflected by data documenting that over 50% of patients need dose 
optimisation during the therapy and 20%-50% of patients experience relapse of the disease and 
require a switch to another medication.​1,3–5  
There is clearly a need for a personalized medicine approach that would allow for a more 
accurate prediction of the appropriate choice of the drug and dose at the initial assessment, and 
communicate chances of long-term success to an individual patient. Several studies addressed 
this issue using multivariate logistic regression to identify possible predictors of outcome. It 
seems that obesity, female sex, failure of another biologic therapy in the past, presence of 
psoriasis on palms and soles and socioeconomic status significantly correlate with worse 
long-term outcomes.​1,4,6​ Unfortunately, the positive predictive values for these factors are very 
low and they are rarely incorporated into clinical decision making. 
We have considered the possibility that the long-term efficacy of biologics is to a certain extent a 
predictable phenomenon and depends on subtle, complex patterns of interactions between 
numerous variables. Machine learning techniques are often able to detect such complex 
patterns and are being increasingly used with success in predicting future trajectories of 
patients’ health in diverse areas such as cancer,​7​ the risk of readmission after hospital 
discharge,​8​ diabetic complications,​9,10​ cardiovascular mortality,​11​ and many others.​12​ Although 
machine learning is frequently employed for drug discovery,​13​ its use for predicting long-term 
outcomes in patients in real-world setting has not been widely investigated.  
Here we examined whether machine learning may aid in predicting long-term responses to 
biologics in psoriasis. We have reanalysed individual patient data from the Danish registry 
cohort, Dermbio, using drug discontinuation as a surrogate measure of treatment failure.​1,4,5 
Methods 
Dataset 
We have used individual patient data from the Danish registry, Dermbio, of 681 psoriasis 
patients who received biologic treatment in one of five academic centers in Denmark between 
2003 and 2013. The structure and the data available in Dermbio have been previously 
described in a detail.​1,4,5,14​ All patient data were anonymized. Therapy outcome measures are 
the length of the treatment series and the cause of drug discontinuation at the last observation 
categorized as being caused by: lack of efficacy, adverse event(s), other (patient’s decision, 
loss to follow-up, not otherwise specified). This dataset has been described in detail in our 
previous publication.​4 
Patient characteristics and available variables used for machine learning algorithms are listed in             
Table 1​.  
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 Table 1.​ Patient characteristics and variables used in the machine learning algorithms 
Category   Data completeness (%) 
Demographics     
    Age (years) 42.8 (9, 83)​1 100 
    Sex Male: 375 
Female: 306 
100 
    Height (cm) 174.1 (110, 198)​1 74.74 
    Weight (kg) 85.6 (30, 180)​1 57.27 
 Number of comorbidities 0: 395 
1: 136 
2: 40 
≥3: 22 
87.08 
Disease-specific     
 Age at diagnosis (years) 25.84 (9, 70)​1 80.32 
 PsA diagnosis No: 454 
Yes: 227 
100 
 Previous MTX No: 543 
Yes: 138 
100 
 Concurrent MTX No: 319 
Yes: 49 
54.04 
 Previous biologic use 0: 464 
1 or more: 217 
100 
 Baseline DLQI 13.56 (0, 32)​1 38.18 
 Baseline PASI 10.5 (0, 39.4) 8.25 
Therapy-specific     
 Biologic initiated Adalimumab: 253 
Etanercept: 196 
Infliximab: 117 
Ustekinumab: 115 
100 
   Treatment series in same patient No: 248 
Yes: 433 
100 
1​mean (range) 
 
Data preprocessing and feature engineering 
In order to apply different machine learning algorithms on psoriasis patients, we performed the 
following preprocessing steps: (1) Correct data types/formats were applied to all features and 
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 meaningful naming conventions were applied to feature names; (2) Features with large number 
of missing values were removed from the training dataset (e.g. PASI after 13 and 52 weeks, 
DLQI after 13 and 52 weeks); (3) Principal Components Analysis (PCA) was applied to detect 
and remove non-predictive features; (4) Predictors which were still missing values were filled 
with Null or appropriate value indicating unavailability of the data.  
Machine Learning 
Understanding the reasons for biologic discontinuation, different supervised machine learning 
techniques and algorithms were used to extract a stochastic model from the patients’ dataset 
and used to predict outcomes of biologic therapy in psoriasis patients whose treatment outcome 
is unknown. In this study, we considered seven different modelling techniques, based upon their 
principally different prediction approaches: (1) Generalized Linear Model (GLM), (2) Logistic 
Regression,(3) Deep Learning, (4) Decision Tree (DT), (5) Random Forest, (6) Gradient 
Boosted Trees, and (7) Support Vector Machine (glm2 package in R, GLM and DT packages in 
Python, RapidMiner simulator).  
We applied different machine learning algorithms on the same dataset to evaluating the 
performance of different approaches and select the learner that performed the best in terms of 
accuracy, interpretability and runtime in a multinomial classification problem. However, as GLM 
and DT outperforms other learners in terms of accuracy, we describe them in more detail in the 
following sections. In order to assess the effectiveness of the models, we applied the 5-fold 
cross validation technique as part of the performance analysis procedure. This technique 
randomly partitions a set of examples into 5 (non-overlapping) sets. Subsequently, a model is 
inferred using each set over 5 iterations and the remaining set is used to evaluate the model 
based upon the accuracy measure (defined in the next section). Since in each iteration a 
different set is used for the evaluation, the final accuracy score is equal to the mean of the 5 
accuracy scores. This assists in evaluating the performance of our machine learning approach 
on some unseen data and identifying over-fitting or under-fitting related issues. 
Performance analysis 
In order to statistically evaluate the performance of learning approaches used in this study, we 
produced confusion tables as a result of classification procedure. A confusion table (matrix) 
reports the number of TP: True Positives; FN: False Negatives, TN: True Negatives and FP: 
False Positives, which can be used to calculate diagnostic accuracy with the following formula:  
ccuracy A =  T P +T NT P +FP +FN+T N   
Receiver operating characteristic (ROC) curves were constructed using R libraries multiROC 
and ggplot2 (downloaded from https://cran.r-project.org/web/packages/) to visualise diagnostic 
utility of the machine learning algorithms. Area under the curve (AUC) was calculated to 
determine which model provided the best prediction by measuring how true positive rate (recall) 
and false positive rate trade off. It is worth noting that the ROC-AUCs were calculated by 
keeping a class and stacking the rest of the groups together, thus converting the multi-class 
classification into binary classification.  
The Bland-Altman analysis​15​ was used to compare the result of prediction on the length of 
treatment series versus the actual treatment length.  
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 Results 
Machine learning accurately predicts the risk of discontinuation 
Drug persistence is often used as a surrogate measure of treatment success in a real-world 
setting because most of biologic drug discontinuation events are due to loss of the therapeutic 
efficacy or adverse events.​1,3,4​ We have applied seven different machine learning algorithms to 
test their accuracy in predicting the risk of drug discontinuation. As shown in ​Table 2​, all 
algorithms predicted the risk of discontinuation with high accuracy ranging from 0.73 (support 
vector machine learning) to 0.82 (generalized linear model, GLM). Thus, we were able to predict 
the treatment outcomes with less than 18.46% classification error, just utilizing the basic health 
information routinely available to every clinician.  
 
Table 2.​ Performance of different machine learning algorithms in predicting the risk of 
discontinuation of the biologic in patients with psoriasis.  
Model Accuracy Standard Deviation Runtime (s) 
Generalized Linear Model 0.815 0.028 1.584 
Logistic Regression 0.759 0.047 3.144 
Deep Learning 0.754 0.043 2.608 
Decision Tree 0.795 0.044 1.413 
Random Forest 0.805 0.039 17.541 
Gradient Boosted Trees 0.810 0.047 53.394 
Support Vector Machine 0.733 0.059 12.55 
 
Generalized Linear Model (GLM) 
Generalized linear models (GLMs) are an extension of traditional linear models that considers 
the response variables with arbitrary error distribution models. This algorithm fits generalized 
linear models to the data by maximizing the log-likelihood and using iteratively reweighted least 
squares method. GLM first was formulated by McCullagh and Nelder​16​ to gather different 
statistical models (e.g. linear regression, logistic regression and Poisson regression) under one 
umbrella. In GLM the computation process for model fitting is parallel, extremely fast, and scales 
extremely well for models with a limited number of predictors with non-zero coefficients. 
To better visualize the usefulness of GLM for predicting the risk of discontinuation, we plotted 
the sensitivity and specificity achieved by this algorithm as a ROC curve (​Fig 1​). The GLM 
algorithm was not only able to accurately predict the overall risk of discontinuation, but also 
robustly predicted the reason of discontinuation, lack of efficacy versus adverse events. The 
confusion matrix describing the performance of the classification model on the set of labeled 
data is available in ​supplementary Figure S1​. 
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 Input optimization reveals patient profile associated with the best long-term response  
Input optimization (or prescriptive analytics) in machine learning describes a process through 
which the algorithm finds a set of characteristics that best fits the desired future outcome. In 
other words, it describes the optimal scenario to correctly determine the classification results for 
unseen inputs. Therefore, using input optimization suitable actions can be suggested to benefit 
from prediction and show the implication of different decision options. 
Here, we were interested in knowing the characteristics under which the patient would continue 
the treatment with less than 10% chance of withdrawal. The results indicated that a patient who 
has at least 90% chance of continuing the treatments fulfill the following criteria: (1) ≥ 23 
year-old at the time of diagnosis (2) ≤ 49 year-old at the time of treatment; (3) receiving 
ustekinumab rather than TNF inhibitor, (4) not diagnosed with psoriasis arthritis (5) baseline 
DLQI ≥ 16; (6) baseline PASI ≥ 9.4; (7) no previous history of biologic failure, (8) weight ≤ 98.9 
kg. 
Decision tree analysis 
The decision tree analysis yielded a slightly lower accuracy in predicting the risk of 
discontinuation compared to GLM (​Table 2 ​and ​supplementary Fig S2​).  However, the 
advantage of the decision tree is the ability to generate interpretable results. A decision tree is a 
flowchart-like collection of nodes intended to predict the value of target variable (in this study, 
treatment discontinuation) using input variables (see ​Table 1​, Methods). Each node represents 
a splitting rule for one specific variable. Depending on the prediction goals, this rule can either 
separate values belonging to different classes or separate them in order to reduce the error in 
an optimal way for the selected parameter criterion. The building of new nodes is repeated until 
the stopping criteria are met. The decision tree algorithm repeatedly selects the branches of the 
tree to obtain subsets of data that contain a larger proportion of the same value of the target 
variable comparing the level above it. Thus, the algorithm determines the appropriate tree 
structure by recursive partitioning, or repeated splitting on the values of attributes until an 
6 
 endpoint is reached. An overview of the inferred tree-like model for psoriasis patients is shown 
in ​supplementary Figure S3​. It shows that the length of the treatment has a meaningful effect 
on the treatment discontinuation rate. For instance, the model revealed that the discontinuation 
that occurs in patients who receive the biologic for less than a year is most likely to be due to 
inefficacy whereas adverse events play an important role in those who are treated for more than 
a year. The algorithm has also highlighted that patients treated with infliximab compared to 
other biologics are more likely to withdraw the treatment due to inefficacy within the first two 
years of starting the treatment regardless of age and gender. These results, although 
confirmatory, underscore the ability of the model to extract meaningful patterns from our 
dataset.  
Predicting the treatment length 
From the practical point of view it is useful to be able not only to predict the risk of treatment 
termination, but also the length of the therapy until the predicted drug discontinuation. We have 
compared the predicted treatment length obtained by the GLM model to the actual recorded 
values using Bland Altman analysis​15​ (​Fig 2​). The Bland Altman approach quantifies the 
agreement between the two measurements in terms of limits of agreement for their mean 
difference. As shown in ​Fig 2A​ the GLA model slightly underestimated the length of treatment 
for patients who stayed on therapy for less than 40 months and overestimated the treatment 
duration for treatment duration >40 months. However, the overall correlation between the 
predicted and the actual treatment duration was excellent (​Fig 2B​) with the  mean absolute 
error (MAE) of only 4.5 months.  
 
Discussion 
Machine learning is emerging as a powerful tool to improve diagnostic accuracy and prediction 
of treatment outcomes in clinical medicine.​12​ Here, for the first time we provide evidence that 
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 machine learning is able to accurately predict the treatment success in psoriasis patients treated 
with biologics. In particular, the GLM model accurately predicted the overall risk of drug 
discontinuation with an accuracy exceeding 80% and was also very efficient in forecasting the 
cause of discontinuation as the loss of efficacy or adverse events. The GLM also accurately 
determined the expected length of treatment with the mean absolute error (MAE) of 4.5 months.  
The very high accuracy of GLM was surprising, taking into account a relatively small dataset 
with a limited set of predictive variables. The dataset from Dermbio only offered 14 different 
variables, all of those easily available in a real world clinical setting (​Table 1​). The simplicity of 
the data structure and high computational efficiency of our algorithms (runtime ranging between 
1.4 to 53 sec on a commercially available laptop) would allow to implement our machine 
learning algorithms in any clinical setting with minimal additional cost. The GLM can easily be 
expanded to include more relevant data for even higher predictive accuracy. It is conceivable, 
than feeding the model with additional information, such as the dose of the biologic, the actual 
characteristics of comorbidities (rather than their number), concomitant medication and the 
clinical characteristics of psoriasis would significantly improve its usefulness. Even with this very 
limited dataset we were able to confirm the importance of obesity and previous failure of a 
biologic as negative predictors of treatment success.​1,4,5,17​ Interestingly, the previously seen 
negative impact of female sex​6,17​ was not detected if the baseline PASI and DLQI data were 
included in the training set. Also, the impact of PsA was negative, in contrast to what has 
previously been suggested from real-world data​3,6,18​ and in a recent metaanalysis.​17​ Our model 
led to a profile of the ideal patient who would most likely benefit from biologic therapy long-term: 
a patient with early-onset psoriasis (before the age of 23 years), the age under 49 years when 
receiving a biologic for the first time, no diagnosis of PsA, and who has a moderate-to-severe 
psoriasis activity (DLQI ≥ 16; PASI ≥ 10) and weight <100 kg. The overall risk of drug 
discontinuation in such a patient is ≤10% which is clearly superior to the mean of the general 
population which is approximately 20% after the first year of treatment and 50% after 3 
years.​4,6,17  
An important advantage of the machine learning models, such as GLM is that they yield results 
in a format which is immediately understandable for the patient and the clinician. Classic 
approach with logistic regression or Cox proportional hazards regression analyses produce 
odds ratios and hazard ratios, respectively, as measures of treatment effect. These are often 
erroneously interpreted as being synonymous with relative risks.​19​ However, the decrease in 
hazard ratio or odds ratio does not correspond to the same percentage of clinical improvement, 
which makes those measures very difficult to use for the patient communication purposes. 
Although odds ratios can in some instances be converted to relative risks,​20​ patients prefer to 
receive information as absolute values, such as the expected number of years to the event or 
the absolute risk of positive or negative outcome.​21,22​ GLM generates such values, the risk of 
drug discontinuation and the projected time on successful therapy, which can conveniently be 
presented as a personalized risk simulator. This approach resembles cardiovascular risk 
calculators widely used in general medicine and cardiology to demonstrate the benefits of 
therapeutic intervention.​23–25  
It is conceivable that machine learning would not only be useful as a tool of precision medicine 
but would also aid in the guideline development. There are numerous psoriasis registries 
collecting data on the outcomes of biologic therapies that together comprise over 60,000 
patients.​14​ In spite of the efforts such as PsoNet, the analysis of the totality of registry data has 
not been accomplished, mostly due to differences in the structure of different databases, 
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 differences in the registration of the outcome and lack of statistical tool to analyse the very 
diverse datasets. The machine learning approach would be a viable approach to analyse the 
long-term outcomes in psoriasis and provide quantitative data informing health care providers 
and policy makers.  
In addition to the already mentioned small sample size, the limitation of this study is the source 
of data from a single country. As extensively discussed elsewhere, the duration of treatment of 
biologics is not only dependent on the objective responses but may be heavily influenced by 
non-medical factors such as access to the medication, reimbursement, or treatment guidelines. 
Thus, the accuracy of our algorithm may vary between different centers and each therapy 
center should establish their own algorithm which reflects local prescription practices. Another 
limitation of this study is its retrospective nature. This is a usual practice in machine learning 
modeling that a dataset is divided into a smaller training set which is used to generate the model 
and a test set used to validate the model. However, the ideal proof of usefulness would be 
through a prospective study in which the choice of treatment performed by the machine learning 
algorithm is compared with the outcomes achieved by the decision of the physician.  
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